Abstract
Many different cellular systems and molecular processes become compromised in Alzheimer’s disease (AD) including proteostasis, autophagy, inflammatory responses, synapse and neuronal circuitry, and mitochondrial function. We focused in this study on mitochondrial dysfunction owing to the toxic neuronal environment produced by expression of Aβ42, and its relationship to other pathologies found in AD including increased neuronal apoptosis, plaque deposition, and memory impairment. Using super-resolution microscopy, we have assayed mitochondrial status in the three distinct neuronal compartments (somatic, dendritic, axonal) of mushroom body neurons of Drosophila expressing Aβ42. The mushroom body neurons comprise a major center for olfactory memory formation in insects. We employed calcium imaging to measure mitochondrial function, immunohistochemical and staining techniques to measure apoptosis and plaque formation, and olfactory classical conditioning to measure learning. We found that mitochondria become fragmented at a very early age along with decreased function measured by mitochondrial calcium entry. Increased apoptosis and plaque deposition also occur early, yet interestingly, a learning impairment was found only after a much longer period of time—10 days, which is a large fraction of the fly’s lifespan. This is similar to the pronounced delay between cellular pathologies and the emergence of a memory dysfunction in humans. Our studies are consistent with the model that mitochondrial dysfunction and/or other cellular pathologies emerge at an early age and lead to much later learning impairments. The results obtained further develop this Drosophila model as a useful in vivo system for probing the mechanisms by which Aβ42 produces mitochondrial and other cellular toxicities that produce memory dysfunction.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Background
Sporadic and genetic forms of Alzheimer’s disease (AD) are characterized by the failure of many different cellular and molecular systems of the brain and other tissues [1,2,3,4]. For instance, the associated neuropathology reported for AD and AD animal models include the generation of toxic cleavage products of APP [5]; impairments in the autophagy-lysosomal pathway leading to protein aggregation [6]; chronic inflammation initiated by microglial activation [3, 7]; synapse failure and loss, reduced dendritic complexity, and impaired connectivity and brain circuit function [8]; glutamate excitotoxicity and cell death [9]; increased oxidative stress [10, 11]; impairments in mitochondrial dynamics and function [12, 13] and others. Despite the broad effects of the disease, research into AD etiology has been driven largely by insights obtained from genetic forms of the disease. Thus, the last two decades have witnessed a concentrated effort to understand the metabolism of amyloid precursor protein (APP), the generation of Aβ oligomers, the deposition of amyloid plaque, and the effects of genetic insults to this molecular system on other aspects of brain function. Although this focus is understandable in retrospect, many other facets of AD neuropathology have remained relatively sketchy. Moreover, extensive efforts made in developing therapeutics based on the APP/Aβ hypothesis have generally failed in clinical trials.
This history has prompted a sense of urgency to develop a better understanding of other aspects of AD neuropathology. Such an understanding will likely lead to two very significant gains. First, providing detailed knowledge of other system failures that occur in AD should lead to insights into their relationships and help establish the hierarchy for the progression of sporadic AD. Second, combinatorial drug therapies may be developed using a mixture of drugs that protect the major system failures in the disease. Without clear knowledge of the initiating trigger(s) for sporadic AD, therapeutic advances will necessarily be combinatorial and require detailed knowledge of the different neuropathologies that define the disease.
Mitochondrial dysfunction represents a hallmark neuropathology for AD and other brain disorders. Indeed, the failure of the mitochondrial system has been found to be an early neuropathology and proposed to be a trigger [14, 15]. Each neuron contains thousands of mitochondria that are thought to be born in the soma and then trafficked to distal sites in axons and dendrites; each organelle offering its functions to remote regions of the neuron including synaptic specializations [16]. They provide many different functions that help maintain neuronal health, the two most recognized being the generation of ATP through respiration and buffering of cytoplasmic calcium. In addition to trafficking to and from distal sites, mitochondria divide in the process of fission and join together in the process of fusion. These processes along with mitochondrial movement fall under the rubric of mitochondrial dynamics.
Drosophila melanogaster has been employed as a model for studying the neuropathology found in diseases that include Parkinson’s disease, Alzheimer’s disease, and amyotrophic lateral sclerosis [17,18,19,20,21]. The organism offers the convenience of small size, rapid generation time, and the ability to generate hundreds of organisms at a relatively low expense, while providing the toxic, cellular disease environment related to genetic forms of the diseases using transgenic approaches analogous to those used for the mouse.
For AD-related neuropathology, many of the prior studies have employed the expression of Aβ42 or other toxic peptides in retinal cells to assay cell death [22,23,24,25]. This approach offers a rapid way of screening cell death based on external morphology but prompts the concern that retinal cells are unique and may not offer the physiology of neurons found in the central brain. Other studies have employed pan-neuronal expression of the toxic peptides [26, 27], but this approach fails to mimic the accepted progression of the disease in humans from the medial temporal lobe to other brain regions. The medial temporal lobe is intimately involved in memory formation, which accounts for the initial symptom displayed by AD patients—forgetfulness.
Here, we have expressed toxic peptide Aβ42 in the mushroom body neurons (MBn), neurons that constitute a major brain center for olfactory memory [28, 29]. We focused our efforts on understanding how impairments in mitochondrial dynamics and function emerge and evolve with the age of the fly and relating these to the temporal evolution of other AD pathologies including apoptosis, plaque deposition, and memory dysfunction. We found that mitochondria are more numerous and smaller in size at a very early age in the Aβ42 environment. Consistent with this, we found that mitochondrial calcium import was also impaired in young flies along with apoptosis and plaque deposition. Interestingly, learning became impaired much later than the mitochondrial deficits and other cellular pathologies.
Methods
Drosophila Husbandry
Fly strains were raised on standard food medium at room temperature. Crosses were made at 70% relative humidity with a 12-h light-dark cycle in a 25 °C incubator. Fly lines used in this study are listed in STAR ★ METHODS.
Immunostaining for Structure Illumination Microscopy
For structured illumination microscopy, brains were isolated from female flies at various ages, processed as previously described and imaged with high-resolution microscope [49]. Additional details are available in STAR ★ METHODS.
Mitochondrial Calcium Entry
Brains were isolated from female flies of various ages and continually perfused with saline solution (124 mM NaCl, 3 mM KCl, 20 mM MOPS, 1.5 mM CaCl2, 4 mM MgCl2, 5 mM NaHCO3, 1 mM NaH2PO4, 10 mM trehalose, 7 mM sucrose, 10 mM glucose; adjusted to pH 7.2 at 25 °C). Neurons were depolarized by adding 15 mM KCl to the perfusion solution. Additional details are available in STAR ★ METHODS.
Cell Death Assay
Brains isolated from female flies of various ages were processed as previously described for immunohistochemistry [49]. The primary antibody against Dcp-1 was used to monitor cell death of MBn. Additional details are available in STAR ★ METHODS.
Amyloid Plaque Staining
Brains from female flies of various ages were dissected and processed as previously described [49]. The isolated brains were immunostained with anti-NC82 and after immunostaining were perfused with 0.5% Thioflavin S for 24 h. Additional details are available in STAR ★ METHODS.
Behavioral Assays
For behavior experiments, young flies were collected and maintained in bottles to various ages. The flies were transferred to vials 12 h prior to the experiments. We used the negatively reinforced, olfactory classical conditioning to assay learning [50]. Additional details are available in STAR ★ METHODS.
Results
Neuronal Mitochondrial are Smaller and More Numerous in the Soma of Flies Expressing Aβ42
We used the Gal4/UAS system to co-express Aβ42 and a mitochondrial-targeted GFP (mito-GFP) [30] to probe the effects of the toxic cellular environment produced by Aβ42 on mitochondrial morphology in neurons. The Gal4 driver used, R13F02-Gal4, is a mushroom body neuron (MBn) specific driver (Fig. 1(a)). The MBs are insect brain structures that regulate the acquisition and storage of olfactory memories [28, 29]. We employed structured illumination microscopy (SIM) which allowed us to characterize the form of individual mitochondria and segment them. We performed this analysis on the mitochondria in a 10-μm3 volume at a standardized location in the somatic, dendritic, and axonal regions of the MBn.
We focused initially on mitochondria in the soma (Fig.1a) and found that, compared with the control group, the Aβ42-expressing animals contained increased numbers of mitochondria in the MB soma as early as 1 day after eclosion (Fig. 1(b, c, f)). We also measured the length, volume, and sphericity of the somatic mitochondria. In Aβ42 animals, we found that mitochondrial length was shortened, the average size reduced, as reflected in surface area and volume, and the sphericity was increased at day 1 (Fig. 1(b, c, f)). In the process of analyzing the mitochondrial morphology, we searched for hemispheric differences in these parameters and found none for both the control and Aβ42 animals (Fig. S1). Because of this, both hemispheres were imaged in each fly, and we collapsed the morphological data from both hemispheres to obtain data on a per fly rather than a per hemisphere basis. The mitochondrial morphological differences observed between control and Aβ42 animals at 1 day of age were preserved at older ages. Aβ42-expressing flies at 5, 10, and 15 days of age also contained more numerous, shorter, smaller, and more spherical mitochondria compared with their age-matched controls (Figures S2, Fig. 1(d, e, g)). Collectively, these data indicate that the expression of Aβ42 induces fragmentation of somatic mitochondria that is evident at 1 day of age and that this fragmentation persists across the first 2 weeks of adulthood.
Mitochondria in Dendrites and Axons are Smaller and More Numerous in Flies Expressing Aβ42, But Detectable Differences Emerge at Later Ages
We then wondered whether the mitochondrial fragmentation observed soon after eclosion in the MBn soma of Aβ42-expressing flies was a neuron-wide effect or whether the other cellular compartments—the axons and dendrites—might exhibit differences. In the dendrites, we observed an increase in mitochondrial number at 1 day-of age, but no significant difference in length, volume or sphericity (Fig. 2a, b). Other mitochondrial defects to include shortening, reduction in size, and increased sphericity were observed at 5, 10, and 15 days of age (Fig. 2c; S3, S4). In the MBn axons, we failed to observe any changes in these mitochondrial morphological parameters at 1, 5, or 10 days of age (Fig. 2d, e; S5, S6). However, by 15 days of age, the mitochondria were more numerous, shortened, smaller, and more spherical in the Aβ42-expressing flies (Fig. 2f).
In summary, detectable mitochondrial fragmentation occurs first in the soma of MBn expressing Aβ42, subsequently in the MBn dendrites, and then in the distal axons. This is somewhat surprising given that current dogma posits that mitochondria are born in the soma from biogenesis followed by transport into the more distal regions of the neuron. It may be that some biogenesis occurs locally, with the toxicity of Aβ42 reduced in axons and dendrites compared with the soma, or the toxicity may be generally equivalent in all parts of the neuron with the mitochondria having differential sensitivity between compartments. Alternatively, all biogenesis could occur in the soma, but gating mechanisms present in the neurites may only allow healthier mitochondria to be transported.
Mitochondria in Aβ42-Expressing Flies Exhibit Impaired Calcium Import
To evaluate the toxic consequences of Aβ42 expression on mitochondria, we measured mitochondrial calcium import in MBn. We used isolated brains (Fig. 3) from control and Aβ42-expressing flies that carried a transgene expressing the calcium reporter, UAS-4mtGCaMP3 [30], targeted to the mitochondrial matrix. These flies also expressed UAS-RFP to provide a normalization signal for the 4mtGCaMP3 responses. The MBn-specific GAL element R13F012-Gal4 was used to drive the transgenes, providing for specific expression in the soma, dendrites, and axons of MBn (Fig. 3a, S5). A total of 15 mM KCl was perfused into the bath containing the isolated brains in order to stimulate calcium influx into the cytoplasm and mitochondria [30]. For consistency, we measured the normalized 4mtGCaMP3 signal from the same somatic area used for experiments examining mitochondrial morphology.
Figure 3b–d show representative fluorescence images from the MB somata and dendrites in control and Aβ42-expressing flies at 1, 5, and 15 days of age. KCl perfusion generated a robust signal from these neurons in control and Aβ42-expressing flies at 1 day of age, with no significant difference in the peak magnitude of the response between the two genotypes (Fig. 3e). In contrast, the mitochondrial calcium import in Aβ42-expressing MBn at 5, 10 (not shown) and 15 days of age was significantly depressed relative to the control, with essentially no import occurring in the Aβ42-expressing MBn at 15 days of age (Fig. 3f, g). These data reveal a functional impairment in the somatic mitochondria from Aβ42-expressing MBn. However, the morphological impairment was significantly different from the control at 1 day of age, but the functional impairment was only trending at this same age. This could indicate that the functional impairment follows the morphological impairment in time, or it could be due to differences in the sensitivity of the two assays. It is notable from the fluorescent assays that the functional impairment extends into the MBn dendrites.
Increased Apoptosis in Aβ42-Expressing MBn
Mitochondria play a fundamental role in regulating cell survival and cell death. Multiple types of stimuli such as activation of the proapoptotic Bcl-2-associated X protein (BAX), oxidants, and stress cause the mitochondria to release caspase-activating proteins like cytochrome c which leads to apoptosis [31,32,33,34]. We wondered whether the expression of Aβ42 specifically in the MBn and the subsequent impairments in mitochondrial structure and function were associated with increased apoptosis. The Drosophila death caspase-1 (Dcp-1)—the homolog of mammalian Caspase-3—is an effector caspase that triggers cell death after activation upon cleavage by initiator caspases. Immunohistochemistry with antibodies to the activated Dcp-1 has been used extensively to quantitate apoptosis [35,36,37]. We stained brains from control and Aβ42-expressing flies of various ages with an anti-Dcp-1 (cleaved) antibody [38,39,40] to determine whether apoptosis was increased.
We observed a significantly increased number of Dcp-1 puncta in the MB somata of Aβ42-expressing flies at 1 day of age compared with their age-matched controls (Fig. 4a, b, g). This measure of apoptosis was markedly increased with age in the experimental flies at 5, 10 (not shown), and 15 days of age (Fig. 4c–f, h, i). Notably, the Dcp-1 puncta were observed only in the MB somata, and not in other regions of the brain consistent with the spatially limited expression of the driver/Aβ42. Collectively, these data reveal an increased level of apoptosis in the somata of Aβ42-expressing flies that parallels the onset and severity of mitochondrial morphological and functional deficits.
Amyloid Plaque Develops Near the Aβ42-Expressing MBn
A main feature of AD is the formation of amyloid plaque in the hippocampus and other brain areas [41,42,43]. To measure amyloid plaque and its co-occurrence with mitochondrial impairment and apoptosis, we stained Aβ42-expressing brains with Thioflavin S, a stain that binds to the amyloid fibrils [23, 44, 45]. We observed a slight increase in Thioflavin S staining in MB somata of Aβ42-expressing brains at 1 day of age compared with the control (Fig. 5a, b, g). The amyloid plaque burden increased at 5, 10 (not shown), and 15 days of age (Fig. 5c–f, h, i). Thus, amyloid plaque burden generally follows the other cellular phenotypes observed—mitochondrial morphological and functional deficits and increased apoptosis.
An Impairment in Olfactory Learning Occurs by 15 days of age for the Aβ42-Expressing Flies
A prominent behavioral consequence of Alzheimer’s disease is the decline of learning and memory ability [45, 46]. However, the developmental relationship between the cellular pathologies such as mitochondrial impairment and the memory impairment has not been fully examined. We assayed olfactory memory tested at 3 min after training in the control and the Aβ42-expressing flies. The expression of Aβ42 in the MBn failed to impair 3-min memory performance at 1, 5, and 10 days of age (Fig. 6). However, we detected a significant memory deficit in the experimental flies at 15 and 20 days (not shown) of age compared with the control genotypes. Interestingly, the 3-min behavioral impairment in the experimental flies fails to follow the early-developing mitochondrial, apoptotic, and amyloid pathology observed in the MB somata and dendrites. Rather, the age-dependent development of memory impairment follows most closely the mitochondrial impairment observed in the MBn axons (Fig. 2d–f, S5, S6).
Discussion
The overriding challenge in finding causes and developing therapies for Alzheimer’s disease (AD) is that the disease causes the failure of many different tissue, cellular, and molecular systems, as noted earlier. The dizzying array of neuropathological consequences is undoubtedly linked, but the hierarchy of disease etiology and progression for sporadic AD remains unclear. Yet, emerging evidence indicates that mitochondrial dysfunction may be one of the more upstream failures, as captured in the mitochondrial cascade hypothesis originally championed by Swerdlow and colleagues [14, 15].
We offer with this study a relatively deep, in vivo investigation of mitochondrial dysfunction due to the toxicity associated with Aβ42 expression. We employed super-resolution microscopy to gain insights into the structural changes that occur in mitochondria due to this toxicity, including quantifying the number, length, volume, and sphericity of mitochondria in the soma of MBn and their dendrites and axons. We found that the mitochondria were shorter and smaller in size, consistent with increased mitochondrial fragmentation that has been reported by others [1]. It has frequently been reported that mitochondrial number or content is reduced in AD, in contrast to our results, but this may be related to disease progression. Increased fragmentation would lead to increased mitochondrial numbers early in the disease with mitochondrial loss observed at later stages due to other contributing factors including perhaps a greater effect of decreased mitochondrial biogenesis. Other researchers have also reported increased mitochondrial number in AD models [47, 48]. We found functional defects in mitochondria due to Aβ42 toxicity in the form of impaired import of calcium. And similar to changes in mitochondrial morphology, mitochondrial function declines with age of the fly. In addition, we provide evidence for increased apoptosis and amyloid plaque deposition in the vicinity of the MBn engineered to express Aβ42. Moreover, a learning impairment develops in flies that express Aβ42 in the MBn. Our studies offer a facile, in vivo model to query the status of mitochondria in the presence of the toxic peptide involved in AD. For instance, the various pathologies develop over a period of 2 weeks, compared with 4–6 months for the most vigorous mouse model for AD. Cost differences for similar experiments using flies versus the mouse would vary by orders of magnitude. The flies and techniques described here could be used to probe the mechanism by which Aβ42 expression leads to structural and functional impairments of neuronal mitochondria and how a dysfunction of the mitochondrial system and/or others leads to a late-developing impairment in memory. In addition, it offers an expedient model to test the protective potential of mitochondrial therapeutics.
We made two observations that are of high interest. First, the abnormal morphology of mitochondria due to Aβ42 expression was observed to occur at different ages in the three compartments of MBn. Mitochondrial fragmentation occurs by 1 day after eclosion in the soma of the MBn, but not until day 5 in the dendrites and day 15 in axons. In addition, we observed an increased number of mitochondria both in the somata and in dendrites at day 1 but not in the axons until day 15. There are two broad explanations for these compartment differences. It may be that the mitochondria in the various compartments are differentially sensitive to the toxicity due to inherent differences in the mitochondria themselves, including, for instance, differences in protein composition. Alternatively, the compartments themselves may present differing levels of toxicity due to differential expression or localization of the toxic peptide or other compartment-specific factors that influence the magnitude of the toxicity. Additional research is required to understand this issue.
Second, the learning impairments occur relatively late, observable at day 15, whereas the mitochondrial structural and functional impairments occur at day 1 along with increased apoptosis and plaque deposition. This observation is consistent with the interpretation that the learning impairment stems from deficits in mitochondrial function and/or the other intervening pathologies. We favor this interpretation, but a counterargument that cannot be dismissed is that each assay has its own inherent sensitivity. It is formally possible that learning impairments also exist at day 1 but that the behavioral assay lacks the sensitivity to extract the difference. This seems unlikely because of the large difference in time-of-onset: the Aβ42-expressing flies show no learning impairment at 10 days of age, yet the mitochondrial impairments are pronounced at day 1. The long delay between the detection of cellular pathologies and the learning impairment, which is essentially 15–20% of the fly’s lifespan, parallel the decades-long progression of the disease in humans.
Conclusions
Collectively, our data show that mitochondrial dysfunction occurs early in hierarchy of cellular behavioral pathologies associated with Alzheimer’s disease and that this function occurs at different times in the somatic, dendritic, and axonal compartments of brain neurons.
Data Availability
All data generated and/or analyzed during the current study are included in this published article and supplementary files.
Abbreviations
- (AD):
-
Alzheimer’s disease
- (APP):
-
amyloid precursor protein
- (MBn):
-
mushroom body neurons
- (mito-GFP):
-
mitochondrial-targeted GFP
- (SIM):
-
structured illumination microscopy
References
Cenini G, Voos W (2019) Mitochondria as potential targets in alzheimer disease therapy: an update. Front Pharmacol 10:902. https://doi.org/10.3389/fphar.2019.00902
Holtzman DM, Morris JC, Goate AM (2011) Alzheimer's disease: the challenge of the second century. Sci Transl Med 3:77sr71. https://doi.org/10.1126/scitranslmed.3002369
Henstridge CM, Hyman BT, Spires-Jones TL (2019) Beyond the neuron-cellular interactions early in Alzheimer disease pathogenesis. Nat Rev Neurosci 20:94–108. https://doi.org/10.1038/s41583-018-0113-1
Gan L, Cookson MR, Petrucelli L, La Spada AR (2018) Converging pathways in neurodegeneration, from genetics to mechanisms. Nat Neurosci 21:1300–1309. https://doi.org/10.1038/s41593-018-0237-7
Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353–356. https://doi.org/10.1126/science.1072994
Martini-Stoica H, Xu Y, Ballabio A, Zheng H (2016) The autophagy-lysosomal pathway in neurodegeneration: a TFEB perspective. Trends Neurosci 39:221–234. https://doi.org/10.1016/j.tins.2016.02.002
Keren-Shaul H et al (2017) A unique microglia type associated with restricting development of Alzheimer's disease. Cell 169:1276–1290 e1217. https://doi.org/10.1016/j.cell.2017.05.018
Iaccarino HF, Singer AC, Martorell AJ, Rudenko A, Gao F, Gillingham TZ, Mathys H, Seo J et al (2016) Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature 540:230–235. https://doi.org/10.1038/nature20587
Wang R, Reddy PH (2017) Role of Glutamate and NMDA Receptors in Alzheimer's disease. J Alzheimers Dis 57:1041–1048. https://doi.org/10.3233/JAD-160763
Kondo T, Asai M, Tsukita K, Kutoku Y, Ohsawa Y, Sunada Y, Imamura K, Egawa N et al (2013) Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Abeta and differential drug responsiveness. Cell Stem Cell 12:487–496. https://doi.org/10.1016/j.stem.2013.01.009
Butterfield DA, Halliwell B (2019) Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. Nat Rev Neurosci 20:148–160. https://doi.org/10.1038/s41583-019-0132-6
Burte F, Carelli V, Chinnery PF, Yu-Wai-Man P (2015) Disturbed mitochondrial dynamics and neurodegenerative disorders. Nat Rev Neurol 11:11–24. https://doi.org/10.1038/nrneurol.2014.228
Cai Q, Tammineni P (2016) Alterations in mitochondrial quality control in Alzheimer's disease. Front Cell Neurosci 10:24. https://doi.org/10.3389/fncel.2016.00024
Perez Ortiz JM, Swerdlow RH (2019) Mitochondrial dysfunction in Alzheimer's disease: role in pathogenesis and novel therapeutic opportunities. Br J Pharmacol 176:3489–3507. https://doi.org/10.1111/bph.14585
Swerdlow RH, Khan SM (2004) A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease. Med Hypotheses 63:8–20. https://doi.org/10.1016/j.mehy.2003.12.045
Misgeld T, Schwarz TL (2017) Mitostasis in neurons: maintaining mitochondria in an extended cellular architecture. Neuron 96:651–666. https://doi.org/10.1016/j.neuron.2017.09.055
Imai Y (2020) PINK1-Parkin signaling in Parkinson's disease: lessons from Drosophila. Neurosci Res. https://doi.org/10.1016/j.neures.2020.01.016
Cha SJ, Choi HJ, Kim HJ, Choi EJ, Song KH, Im DS, Kim K (2020) Parkin expression reverses mitochondrial dysfunction in fused in sarcoma-induced amyotrophic lateral sclerosis. Insect Mol Biol 29:56–65. https://doi.org/10.1111/imb.12608
Garrido-Maraver J, Loh SHY, Martins LM (2020) Forcing contacts between mitochondria and the endoplasmic reticulum extends lifespan in a Drosophila model of Alzheimer's disease. Biol Open 9:bio047530. https://doi.org/10.1242/bio.047530
Wang X et al (2016) Establishment of a Drosophila AD model. J Biol Methods 3:e43. https://doi.org/10.14440/jbm.2016.61
Wang X, Wang Z, Chen Y, Huang X, Hu Y, Zhang R, Ho MS, Xue L (2014) FoxO mediates APP-induced AICD-dependent cell death. Cell Death Dis 5:e1233. https://doi.org/10.1038/cddis.2014.196
Cutler T, Sarkar A, Moran M, Steffensmeier A, Puli OR, Mancini G, Tare M, Gogia N et al (2015) Drosophila eye model to study neuroprotective role of CREB binding protein (CBP) in Alzheimer's Disease. PLoS One 10:e0137691. https://doi.org/10.1371/journal.pone.0137691
Iijima K, Iijima-Ando K (2008) Drosophila models of Alzheimer's amyloidosis: the challenge of dissecting the complex mechanisms of toxicity of amyloid-beta 42. J Alzheimers Dis 15:523–540. https://doi.org/10.3233/jad-2008-15402
Povellato G, Tuxworth RI, Hanger DP, Tear G (2014) Modification of the Drosophila model of in vivo Tau toxicity reveals protective phosphorylation by GSK3beta. Biol Open 3:1–11. https://doi.org/10.1242/bio.20136692
Dourlen P (2017) Identification of Tau toxicity modifiers in the Drosophila eye. Methods Mol Biol 1523:375–389. https://doi.org/10.1007/978-1-4939-6598-4_26
Iijima K, Chiang HC, Hearn SA, Hakker I, Gatt A, Shenton C, Granger L, Leung A et al (2008) Abeta42 mutants with different aggregation profiles induce distinct pathologies in Drosophila. PLoS One 3:e1703. https://doi.org/10.1371/journal.pone.0001703
Lee S, Bang SM, Hong YK, Lee JH, Jeong H, Park SH, Liu QF, Lee IS et al (2016) The calcineurin inhibitor Sarah (Nebula) exacerbates Abeta42 phenotypes in a Drosophila model of Alzheimer's disease. Dis Model Mech 9:295–306. https://doi.org/10.1242/dmm.018069
Busto GU, Cervantes-Sandoval I, Davis RL (2010) Olfactory learning in Drosophila. Physiology (Bethesda) 25:338–346. https://doi.org/10.1152/physiol.00026.2010
Davis R, SnapShot L (2015) olfactory classical conditioning of Drosophila. Cell 163:524–524 e521. https://doi.org/10.1016/j.cell.2015.09.043
Drago I, Davis RL (2016) Inhibiting the mitochondrial calcium uniporter during development impairs memory in adult Drosophila. Cell Rep 16:2763–2776. https://doi.org/10.1016/j.celrep.2016.08.017
Chauhan D et al (2018) BAX/BAK-induced apoptosis results in caspase-8-dependent IL-1beta maturation in macrophages. Cell Rep 25:2354–2368 e2355. https://doi.org/10.1016/j.celrep.2018.10.087
Bock FJ, Tait SWG (2020) Mitochondria as multifaceted regulators of cell death. Nat Rev Mol Cell Biol 21:85–100. https://doi.org/10.1038/s41580-019-0173-8
Green DR, Reed JC (1998) Mitochondria and apoptosis. Science 281:1309–1312. https://doi.org/10.1126/science.281.5381.1309
Wang C, Youle RJ (2009) The role of mitochondria in apoptosis. Annu Rev Genet 43:95–118. https://doi.org/10.1146/annurev-genet-102108-134850
Song Z, McCall K, Steller H (1997) DCP-1, a Drosophila cell death protease essential for development. Science 275:536–540. https://doi.org/10.1126/science.275.5299.536
Akagawa H, Hara Y, Togane Y, Iwabuchi K, Hiraoka T, Tsujimura H (2015) The role of the effector caspases drICE and dcp-1 for cell death and corpse clearance in the developing optic lobe in Drosophila. Dev Biol 404:61–75. https://doi.org/10.1016/j.ydbio.2015.05.013
Ryoo HD, Bergmann A (2012) The role of apoptosis-induced proliferation for regeneration and cancer. Cold Spring Harb Perspect Biol 4:a008797. https://doi.org/10.1101/cshperspect.a008797
Florentin A, Arama E (2012) Caspase levels and execution efficiencies determine the apoptotic potential of the cell. J Cell Biol 196:513–527. https://doi.org/10.1083/jcb.201107133
Sarkissian T, Timmons A, Arya R, Abdelwahid E, White K (2014) Detecting apoptosis in Drosophila tissues and cells. Methods 68:89–96. https://doi.org/10.1016/j.ymeth.2014.02.033
Loewen C, Boekhoff-Falk G, Ganetzky B, Chtarbanova S (2018) A Novel mutation in brain tumor causes both neural over-proliferation and neurodegeneration in adult Drosophila. G3 (Bethesda) 8:3331–3346. https://doi.org/10.1534/g3.118.200627
Hardy J, Allsop D (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 12:383–388. https://doi.org/10.1016/0165-6147(91)90609-v
Bloom GS (2014) Amyloid-beta and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol 71:505–508. https://doi.org/10.1001/jamaneurol.2013.5847
Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ et al (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316:750–754. https://doi.org/10.1126/science.1141736
Greeve I, Kretzschmar D, Tschäpe JA, Beyn A, Brellinger C, Schweizer M, Nitsch RM, Reifegerste R (2004) Age-dependent neurodegeneration and Alzheimer-amyloid plaque formation in transgenic Drosophila. J Neurosci 24:3899–3906. https://doi.org/10.1523/JNEUROSCI.0283-04.2004
Chiang HC, Wang L, Xie Z, Yau A, Zhong Y (2010) PI3 kinase signaling is involved in Abeta-induced memory loss in Drosophila. Proc Natl Acad Sci U S A 107:7060–7065. https://doi.org/10.1073/pnas.0909314107
Lazarov O, Lee M, Peterson DA, Sisodia SS (2002) Evidence that synaptically released beta-amyloid accumulates as extracellular deposits in the hippocampus of transgenic mice. J Neurosci 22:9785–9793
Onyango IG, Dennis J, Khan SM (2016) Mitochondrial dysfunction in Alzheimer's disease and the rationale for bioenergetics based therapies. Aging Dis 7:201–214. https://doi.org/10.14336/AD.2015.1007
Calkins MJ, Manczak M, Mao P, Shirendeb U, Reddy PH (2011) Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease. Hum Mol Genet 20:4515–4529. https://doi.org/10.1093/hmg/ddr381
Cervantes-Sandoval I, Phan A, Chakraborty M, Davis RL (2017) Reciprocal synapses between mushroom body and dopamine neurons form a positive feedback loop required for learning. Elife 6:e23789. https://doi.org/10.7554/eLife.23789
Phan A et al (2019) Stromalin constrains memory acquisition by developmentally limiting synaptic vesicle pool size. Neuron 101:103–118 e105. https://doi.org/10.1016/j.neuron.2018.11.003
Funding
This research was supported by NIH grant 5R01AG049037.
Author information
Authors and Affiliations
Contributions
X.W. and R.L.D. conceptualized the project together. X.W. planned and performed all of the experiments, data analysis and interpretation, and figure design and wrote the initial draft of the manuscript. R.L.D. acquired the funding, helped with planning the experiments, supervised the overall execution of the project, provided feedback on data interpretation, and edited the manuscript along with X.W. All the authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Competing Interests
The authors declare that they have no competing interests.
Ethical Approval and Consent to Participate
Not applicable.
Consent for Publication
Not applicable.
Authors’ Information
Not applicable.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
ESM 1
(PDF 26861 kb)
Rights and permissions
About this article
Cite this article
Wang, X., Davis, R.L. Early Mitochondrial Fragmentation and Dysfunction in a Drosophila Model for Alzheimer’s Disease. Mol Neurobiol 58, 143–155 (2021). https://doi.org/10.1007/s12035-020-02107-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12035-020-02107-w